Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410904 · ClinicalTrials.gov registry record · Phase 2
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
A Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00410904: Completed Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00410904 is a Phase 2 study of Recurrent Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 143-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00410904, a Phase 2 study of Recurrent Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving AZD2171 together with pemetrexed disodium may kill more tumor cells.
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v 1.0) for target lesions and assessed by MRI or CT: Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD Overall Response (OR) = CR + PR, the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest me
Conditions Studied
Interventions
- DRUG pemetrexed disodium
- DRUG cediranib maleate
Study Locations (2)
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
What the finished NCT00410904 record still lists
NCT00410904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 143-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Recurrent Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pemetrexed disodium is the first listed.
NCT00410904 reports a single indexed study location in Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT00410904 about?
NCT00410904 is a clinical study titled "AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer". This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also s...
What is the current status of trial NCT00410904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-10. Estimated completion is 2014-03.
What conditions does trial NCT00410904 study?
This clinical trial studies the following conditions: Recurrent Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT00410904?
The interventions under investigation include: pemetrexed disodium (DRUG), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00410904?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00410904 being conducted?
This trial has 2 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00410904's enrollment target sits among peer trials
60 7th of 15 higher than 9 of 15 other Recurrent Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
COMPLETED · Phase 2
-
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia